Investment Rating - The report indicates a positive investment outlook for the Chinese oral beauty market, projecting a market size exceeding 25 billion yuan by 2025, despite a slowdown in growth rate compared to previous years [2][12]. Core Insights - The Chinese oral beauty market is experiencing a transformation from "marketing-driven" to "science-driven," influenced by policy, technology, and consumer demand, with second and third-tier cities and younger demographics identified as future growth engines [3][22]. - The market is characterized by high concentration, with major brands entering the space, and a significant increase in online sales channels, particularly through platforms like Douyin [8][24]. - The demand for anti-aging and whitening products continues to grow, establishing these as the two core segments within the oral beauty market [26][31]. Summary by Sections 1. Market & Industry Trends - China has become the second-largest consumer market for oral beauty products in East Asia, following Japan, with a market share of 30.7% in the Asia-Pacific region [12]. - The market is projected to grow, with a forecast of over 25 billion yuan by 2025, despite a slight decrease in growth rate [12][15]. - The industry is witnessing a surge in brand entries, with both domestic and international brands targeting the Chinese market [15][22]. 2. Consumer Analysis - The primary consumer demographic for oral beauty products on Douyin is women aged 31-40, with younger consumers (18-23) showing heightened interest [41][45]. - The interest in oral beauty topics is particularly strong in new first-tier, second-tier, and third-tier cities, with users most active on weekends [47][50]. 3. Product & Efficacy Trends - The report identifies a shift towards functional foods and traditional supplements, with a notable lack of products passing health food certifications [55][58]. - Popular efficacy ingredients include plant extracts, collagen, probiotics, and B vitamins, with a growing consumer preference for products that emphasize scientific validation of ingredients [72][83]. - The market is seeing a rise in innovative product forms, such as snack-like formats, driven by younger consumers seeking convenience [62][66].

近日，小红书在其官方账号"薯管家"上发布了关于"拉踩测评"的治理公告。公告显示，禁止拉踩的形式包括"竞对 抹黑攻击""误导性对比""非真实舆论引导"，对于出现这类"拉踩"内容及水军账号，平台会严格处置内容及背后账 号，同时相关品牌作为利益主体也会被连带限流、扣品牌分。 薯管家 8/00 2 关注 小红书 关于重点打击 品牌在站内拉踩行为的 治理公告 NC Now DN视频 公告显示，小红书定义的"拉踩测评"指通过刻意贬低、恶意对比竞品（如护肤品、母婴用品、数码产品等）的方 式，虚构评测结果或放大产品缺陷，从而达到抬高自身品牌、误导用户决策的内容。 其常见形式包括：一是竞对抹黑攻击，即未对产品做出真实体验及测评，仅在品牌商业合作关系下发布虚假的抹 黑攻击竞对的各类内容。单方面无根据发布多个产品的评分/排行榜/红黑榜，或者对测评产品做出有失公允的负 面评价及贬损。二是误导性对比，即围绕产品外观、使用场景、参数性能、性价比、产品功效等方面，刻意选择 将本品优势与竞对劣势的做不公正局部对比，贬低竞对、同时误导消费者的测评内容。三是非真实舆论引导，即 由测评作者本人或品牌招募水军在测评类笔记评论区做出某品牌的贬低攻击、 ...

Market Overview - As of 13:59 today, the Shanghai Composite Index stands at 3359.41 points, above the six-month moving average, with a change of 0.36% [1] - The total trading volume of A-shares today is 938.825 billion yuan [1] Stocks Breaking Six-Month Moving Average - A total of 166 A-shares have surpassed the six-month moving average today [1] - Notable stocks with significant deviation rates include: - Dahongli (300865) with a deviation rate of 17.40% and a daily increase of 19.98% [1] - Guangshentang (300436) with a deviation rate of 9.85% and a daily increase of 12.37% [1] - Huaxibio (688363) with a deviation rate of 6.23% and a daily increase of 7.12% [1] Stocks with Smaller Deviation Rates - Stocks with smaller deviation rates that have just crossed the six-month moving average include: - Fusenmei (300629) with a deviation rate of 5.78% and a daily increase of 12.98% [1] - Weidao Nano (600037) with a deviation rate of 5.44% and a daily increase of 7.16% [1] - Huaping Co. (603320) with a deviation rate of 5.10% and a daily increase of 7.27% [1]

Core Viewpoint - The cosmetics retail sales in China for January to April 2025 showed a year-on-year increase of 4%, underperforming the overall retail market by 0.7 percentage points, but this represents an improvement compared to 2024. The industry is characterized by four key trends: innovation in personal care products, breakthroughs in ingredient technology, rising emotional consumption, and the continuation of affordable consumption [1][3]. Investment Recommendations - The company recommends increasing holdings in the personal care sector, highlighting quality companies that benefit from product innovation and opportunities in Douyin channels, with key recommendations including Ruoyuchen (003010), Dengkang Oral (001328), and Runben Co. [2] - In the beauty sector, structural opportunities are identified, with key recommendations for companies like Jinbo Biological, Juzi Biological, and Marubi Co. that are positioned to benefit from the collagen restructuring trend. Additionally, brands like Maogeping, Shumei Co., Proya (603605), and Shanghai Jahwa (600315) are expected to gain from the overall increase in domestic market share [2]. - Companies expected to bottom out and potentially see a turning point include Lafang Household (603630), Shuiyang Co. (300740), Betaini (300957), Furuida (600223), Huaxi Biological, Fulejia (301371), Meilitiantian Medical Health, and Qingsong Co. (300132) [2]. Industry Overview - Demand remains stable, with the rise of domestic brands in the beauty and personal care sectors accelerating. The cosmetics retail sales for January to April 2025 increased by 4% year-on-year, which is a 0.7 percentage point underperformance compared to the overall retail market, but shows improvement from 2024. The overall demand is stable, with leading domestic brands performing well and the rise of new domestic brands spreading from beauty to personal care categories [3][4]. Trends - The industry is witnessing several trends: 1) Personal care transformation with new products in traditional categories, supported by content e-commerce creating a favorable environment for new product launches [4]. 2) Ingredient innovation, particularly in collagen restructuring, with various types and structural innovations expanding application scenarios [4]. 3) Emotional consumption, where cultural, stylistic, and experiential demands are driving the growth of domestic trends in cosmetics and fragrances [4]. 4) Affordable consumption, where the trend for cost-effectiveness continues under supply-demand resonance, benefiting strong supply chains and well-operated brands [4]. Key Companies - Looking ahead to 2025, the market risk appetite is expected to recover significantly. The beauty sector is characterized by substantial changes and a clear trend of rising domestic brands, indicating strong growth potential and leadership in new consumption [5]. The differentiation among brands is increasing, emphasizing the selection of high-growth targets driven by product innovation and attention to marginal improvements [5].

Group 1 - The core viewpoint of the articles highlights the evolution of the beauty industry towards a "beauty lifestyle" that integrates health and beauty, with a significant focus on oral beauty products [1][2] - Major companies like Shiseido and Unilever are expanding into the oral beauty market, with Unilever targeting China as the first overseas market for its OLLY brand [1][2] - The global oral beauty market is projected to grow from $4.45 billion in 2021 to $9.81 billion by 2031, reflecting a compound annual growth rate (CAGR) of 7.7% [1] Group 2 - The trend of "food and beauty integration" is emerging, with companies like Meiji and PepsiCo launching innovative products that combine health and beauty benefits [2][5] - Domestic companies in China are also following this trend, with products like hyaluronic acid sparkling water and milk that emphasize skin nourishment [7][8] - The oral beauty market is evolving from traditional forms like capsules to more consumer-friendly formats, indicating a shift towards everyday products [8][11] Group 3 - The concept of "internal and external nourishment" is gaining traction, with companies like Shiseido planning to launch a new health product line by 2024 [16][17] - Many beauty companies are transforming into health and beauty conglomerates, with Unilever acquiring various health brands to build a global health brand matrix [17][19] - The integration of health and beauty is becoming a standard in mature markets, with a focus on comprehensive care that addresses both internal and external factors affecting skin health [19][20] Group 4 - The oral beauty market is experiencing regional differences, with the Chinese market showing significant growth potential, expected to exceed 25.57 billion yuan by 2025 [27] - Chinese consumers are more focused on efficacy rather than natural ingredients, and there is a cultural hesitance towards supplement forms due to traditional beliefs [27][28] - The concept of "new Chinese-style beauty drinks" is emerging, combining modern oral beauty with traditional Chinese medicine principles, reflecting a growing market for health-oriented beverages [31][32]

Market Overview - The Shanghai Composite Index closed at 3363.48 points, above the six-month moving average, with an increase of 0.48% [1] - The total trading volume of A-shares reached 763.885 billion yuan [1] Stocks Breaking Six-Month Moving Average - A total of 155 A-shares have surpassed the six-month moving average today [1] - Notable stocks with significant deviation rates include: - Dahongli (300865) with a deviation rate of 17.40% and a daily increase of 19.98% [1] - Huaxi Biological (688363) with a deviation rate of 6.33% and a daily increase of 7.22% [1] - Gehua Cable (600037) with a deviation rate of 4.90% and a daily increase of 6.61% [1] Stocks with Smaller Deviation Rates - Stocks with smaller deviation rates that have just crossed the six-month moving average include: - Beizi Technology (North Self Technology) and Naconoer with minor deviation rates [1] - Other stocks with notable performance include: - ST Chengchang (001270) with a deviation rate of 4.85% and a daily increase of 4.65% [1] - Zhejiang Shuwen (600633) with a deviation rate of 4.64% and a daily increase of 5.12% [1]

Market Overview - The Shanghai Composite Index closed at 3363.48 points, above the five-day moving average, with an increase of 0.48% [1] - The total trading volume of A-shares reached 763.885 billion yuan [1] Stock Performance - A total of 929 A-shares broke through the five-day moving average today [1] - Stocks with significant deviation rates include: - Laisai Laser (21.79%) - Kangliyuan (11.86%) - Mankalon (10.78%) [1] Top Stocks by Deviation Rate - Laisai Laser (871263): - Today's change: +30.00% - Turnover rate: 38.87% - Five-day moving average: 19.53 yuan - Latest price: 23.79 yuan - Deviation rate: 21.79% [1] - Kangliyuan (301287): - Today's change: +17.32% - Turnover rate: 32.85% - Five-day moving average: 35.00 yuan - Latest price: 39.15 yuan - Deviation rate: 11.86% [1] - Mankalon (300945): - Today's change: +19.98% - Turnover rate: 18.47% - Five-day moving average: 22.66 yuan - Latest price: 25.10 yuan - Deviation rate: 10.78% [1] Additional Notable Stocks - Beitaini (300957): - Today's change: +11.83% - Turnover rate: 4.22% - Five-day moving average: 45.58 yuan - Latest price: 49.44 yuan - Deviation rate: 8.48% [1] - Jiuling Technology (873305): - Today's change: +10.00% - Turnover rate: 13.81% - Five-day moving average: 42.79 yuan - Latest price: 46.20 yuan - Deviation rate: 7.98% [1]

Core Viewpoint - Hyaluronic acid is not just a moisturizing agent but has vast applications in pharmaceuticals, medical aesthetics, skincare, and health foods, indicating a significant growth potential in various sectors [1][2][4]. Industry Overview - The hyaluronic acid market is primarily dominated by three major companies: Huaxi Biological, Aimeike, and Haohai Biological, collectively referred to as the "big three" in the industry, with market capitalizations exceeding 100 billion yuan for Huaxi Biological and Aimeike at one point [2][3]. - In 2023, China accounted for 84% of the global hyaluronic acid raw material sales, establishing itself as the largest producer, with Shandong province being the key production hub [7][8]. Application Scenarios - Hyaluronic acid is widely used in the medical aesthetics sector, particularly in non-surgical procedures like water light needles and injection fillers, due to its excellent moisture retention and filling properties [3][4]. - The applications of hyaluronic acid have expanded from ophthalmology to include various medical fields, such as joint lubrication, vascular permeability regulation, and wound healing [5][14]. Technological Advancements - Huaxi Biological has significantly improved the production efficiency of hyaluronic acid through microbial fermentation technology, increasing the yield from 3g/L to 12-14g/L and reducing production time from 72 hours to 18 hours [8][13]. - The introduction of cross-linking technology has transformed hyaluronic acid from a liquid to a gel state, extending its metabolic duration in the body and facilitating its use in aesthetic procedures [5][8]. Market Challenges - The industry faces challenges such as overcapacity and price wars due to an influx of competitors, leading to a significant drop in raw material prices from thousands to hundreds of yuan [8][9]. - Major companies have reported varying degrees of performance challenges since 2022, with Huaxi Biological's functional skincare and food businesses experiencing declines [9]. Future Directions - The future of hyaluronic acid lies in expanding its applications in medical devices and developing new products that combine hyaluronic acid with other ingredients for enhanced therapeutic effects [11][12]. - Companies are exploring regenerative capabilities of hyaluronic acid, focusing on its dual functions of filling and regeneration, which could lead to innovative product offerings [12][14].

Market Overview - As of 10:30 AM today, the Shanghai Composite Index stands at 3352.43 points, above the six-month moving average, with a change of 0.15% [1] - The total trading volume of A-shares today is 568.946 billion yuan [1] Stocks Performance - A total of 138 A-shares have surpassed the six-month moving average today, with notable stocks showing significant deviation rates [1] - The stocks with the highest deviation rates include: - Dahongli (300865) with a deviation rate of 17.40%, closing at 27.74 yuan, up 19.98% [1] - Huaxi Biological (688363) with a deviation rate of 6.97%, closing at 54.41 yuan, up 7.87% [1] - *ST Chengchang (001270) with a deviation rate of 5.20%, closing at 36.55 yuan, up 5.00% [1] Additional Stocks with Notable Performance - Other stocks with significant performance include: - Zhejiang Shuwenhua (600633) with a deviation rate of 5.17%, closing at 13.62 yuan, up 5.66% [1] - Gehua Cable (600037) with a deviation rate of 4.76%, closing at 7.73 yuan, up 6.47% [1] - Stocks with smaller deviation rates that have just crossed the six-month line include Aotai Biological, Chitianhua, and Emei Mountain A [1]

Group 1 - The pharmaceutical sector has shown strong performance recently, with healthcare and pharmaceutical stocks gaining traction on the first trading day of June [1] - The Kexin Pharmaceutical Index ETF (588700) rose over 2% as of the report, with a turnover rate exceeding 6% and a premium trading rate of 0.12% [1] - Notable stocks within the ETF include Microchip Biotech, which increased by over 14%, and several others like Shenzhou Cell, Sangfor Biopharma, and Huaxi Biotech, which saw gains of over 8% [1] Group 2 - The Kexin Pharmaceutical Index ETF closely tracks the Shanghai Stock Exchange's Kexin Biopharmaceutical Index, which includes 50 large-cap companies in the biopharmaceutical and related sectors [1] - In May, the pharmaceutical sector performed strongly, with the Shenwan Pharmaceutical Biotech Index rising by 6.42%, second only to the environmental sector [1] - The approval of 11 new innovative drugs in the last week of May indicates a peak period for innovation drugs, suggesting a positive outlook for the sector [2] Group 3 - Guojin Securities highlighted that the recent approval of 11 new innovative drugs by the National Medical Products Administration could boost the performance of related companies [2] - The ongoing support for innovative drugs from policy measures, along with significant overseas licensing deals, is expected to sustain the sector's growth [2] - Huafu Securities recommends focusing on innovative drugs as a long-term investment strategy, particularly those with clear catalysts and strong performance trends [2]